Medical Microinstruments (MMI) raised $125 million in Series D financing to expand adoption of its Symani Surgical System and explore new microsurgery uses, including an experimental program aimed at Alzheimer’s disease. The company is using the capital to broaden the reach of robotic microsurgery platforms beyond current use cases. MMI also highlighted pipeline development activity, describing investigation of additional applications for microsurgery beyond its core surgical workflows. The Alzheimer’s-related effort remains experimental, reflecting the company’s longer-term intent to translate platform capability into neurodegenerative therapeutic exploration. The raise underscores ongoing investor interest in enabling technologies that can be deployed across clinical specialties, not only in new drug candidates. By funding both commercial expansion of its robotic system and preclinical/early development work for new indications, MMI’s financing ties capital allocation directly to platform scaling and R&D extension.